Boston Scientific Corporation (BSX) is a Healthcare stock trading at $49.39 (as of 2026-08-20), with a market capitalization of $71.58B and a trailing P/E of 19.5. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Boston Scientific develops, manufactures, and markets interventional medical devices worldwide, including diagnostic and treatment devices for gastrointestinal and pulmonary conditions, urological and pelvic conditions, cardiac rhythm therapies, and implantable defibrillators and pacemakers, as well as remote patient management systems.
Its profit engine is the sale of interventional medical devices across three specialty areas (MedSurg, Rhythm and Neuro, and Cardiovascular), spanning implantable cardiac therapies, other procedure-focused treatment devices, and remote patient management systems.
Business quality (Solid): Clear segment framework and product categories are provided, but segment revenue split for all three official reportable segments is not provided here, so a full, clean segment revenue breakdown cannot be constructed from the given facts.
Valuation: At 20× earnings, BSX trades 39% below the Medical Equipment average (32×). Note: one-time items can distort reported P/E.
| Price | $49.39 |
| Market Cap | $71.58B |
| P/E Ratio | 19.5 |
| EV / EBITDA | 12.0 |
| Price / Book | 2.84 |
| Price / Sales | 3.41 |
| FCF Yield | 3.7% |
| DCF Value (model) | $33.48 |
| DCF Upside vs Price | -32.2% |
| Revenue (TTM) | $20.07B |
| Net Margin | 14.4% |
| Revenue Growth (YoY) | 7.5% |
| EPS Growth (YoY) | 14.8% |
| FCF Growth (YoY) | 28.4% |
| Altman Z-Score | 3.29 (safe) |
| Piotroski F-Score | 8/9 (strong) |
| Stock P/E | 19.5 |
| Sector P/E (Healthcare) | 21.6 |
| Industry P/E (Medical Equipment) | 32.9 |
| vs Sector | -9.7% |
| vs Industry | -40.7% |
| Top Institutional Holder | VANGUARD GROUP INC ($13.32B) |
| Institutional Holders Tracked | 10 |
| Congressional Trades (recent) | 10 |
| Sector | Healthcare |
| Industry | Medical Equipment |
| CEO | Michael F. Mahoney |
| Employees | 53,000 |
| Country | US |
| IPO Date | 1992-05-19 |
Data as of 2026-08-20.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.